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The role of insulin-like growth factor binding protein 2 (IGFBP2) in cancer is unclear. In
general, IGFBP2 is considered to be oncogenic and its expression is often observed to be
elevated in cancer. However, there are a number of conflicting reports in vitro and in vivo
where IGFBP2 acts in a tumor suppressor manner. In this mini-review, we discuss the
factors influencing the variation in IGFBP2 expression in cancer and our interpretation of
these findings.
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INTRODUCTION
Insulin-like growth factor binding protein 2 is a member of
the family of six IGF-binding proteins, IGFBP1–6, these pro-
teins bind with high-affinity to IGF1 and IGF2 (1); in addition,
there is also a low affinity for insulin (2). Other IGF-binding
proteins such as the CCN family retain the name as IGFBPs,
although these have ~100-fold lower affinity for IGF1 and IGF2
(1, 3, 4). IGFBP2 has the ability to bind insulin, IGF1 and IGF2
with an increased affinity for the latter (2, 5). IGFBP2 and the
other family members have been proposed to suppress tumor
development through binding IGFs preventing binding to their
receptor and thereby preventing IGF driven tumorigenesis (6).
However, despite this suppressive function, there are also studies
that demonstrate oncogenic functions including promoting pro-
liferation, driving invasion, and suppressing apoptosis (7). These
effects appear to be independent of its ability to bind the IGFs and
instead promote invasion and proliferation through interaction
with integrins (8, 9).
Insulin-like growth factor binding protein 2 has been pro-
posed as a potential biomarker in various cancer types, including
gliomas (10–18), prostate (19–27), ovarian (28–33) colorectal
(34–40) and acute myeloid leukemia (13, 41, 42), acute lym-
phoblastic leukemia (43, 44) pancreatic (45–48), lung (49–52),
cervical cancer (53), breast (54, 55) including triple negative breast
cancer (56), liver (57–60), head and neck (61), rhabdomyosar-
coma (62), non-seminomatous germ cell cancer (63), gastric
(64), synovial sarcoma (65), adrenocortical (66), and Wilm’s
tumors (67). These studies have identified changes in tissue lev-
els or circulating plasma levels of IGFBP2 protein, although it
is not yet clear whether tumor or circulating levels are bet-
ter as cancer biomarkers as each approach provides conflicting
data. Despite this extensive investigation, IGFBP2 has not yet
been implemented as a cancer biomarker due to contradictory
findings as to whether IGFBP2 is up- or down-regulated in
different cancers. There are multiple factors, which can influ-
ence IGFBP2 expression and which can alter our interpreta-
tion of these findings; in the following sections, we propose
that future experiments should aim to account for these fac-
tors in order to improve our understanding of IGFBP2’s role in
cancer.
METABOLIC/DIETARY MODULATION OF IGFBP2
Insulin-like growth factor binding protein 2 is being evaluated
as a potential cancer biomarker as it is a secreted protein that is
readily detected in a patients’ plasma; higher levels have repeat-
edly been associated with disease severity in prostate cancer and
gliomas. However, there are also inconsistent finding, which makes
evaluation of IGFBP2’s oncogenic/tumor suppressive role diffi-
cult and also questions the suitability of IGFBP2 as a biomarker
(68). Therefore, it is important to consider whether there are con-
founding factors, which obscure our interpretation. Plasma levels
of IGFBP2 are known to inversely correlate with obesity/body
mass index (BMI) (69–76), and insulin resistance. In addition,
diet (77), fasting (78), age, and physical activity (79) also influence
IGFBP2 plasma levels. If not included within the study design,
these factors are likely to hinder our evaluation of IGFBP2 as a
biomarker. The importance of combining these parameters along
with measurements of IGFBP2 levels is demonstrated by Probst-
Hensch et al. (80). By combining BMI and the levels of IGFBP2
and IGFBP3 in assessment of breast cancer patient survival, the
authors demonstrated that without correction for BMI neither
IGFBP2 nor IGFBP3 were predictive of overall survival, whereas
inclusion of BMI identified that higher IGFBP2 levels to be a bene-
ficial prognosticator. This is an interesting finding as it is generally
considered that IGFBP2 is oncogenic in breast cancer (55, 81);
however, these other studies did not correct for factors such as
BMI. Similarly, the influence of obesity has been examined with
respect to the levels of IGFBP2, with lower levels observed in obese
patients, which has been proposed to be a result of hyperinsuline-
mia, with insulin suppressing IGFBP2 expression (82). This has
been linked with the subsequent increase in proliferation medi-
ated by free-IGFs and thereby increasing the risk of cancer in
obese individuals (82). In some respects, this interpretation is
complemented by data in IGFBP2 transgenic mice, which have
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reduced body mass (83) and incidence of colorectal adenomas in
experimental models (84).
REGULATION OF IGFBP2 EXPRESSION AT A CELLULAR LEVEL
Given the difficulties in accurately associating plasma levels of
IGFBP2 with cancer patient prognosis or disease progression,
as well as reports demonstrating a lack of concordance between
tumor immunohistochemistry (IHC) and serum levels of IGFBP2
(12, 52, 85–87), it may be more meaningful to assess the expression
of IGFBP2 within the tumor itself. IGFBP2 is mainly expressed
by the liver, adipose, and reproductive tissues and tissues of the
central nervous system (4). However, IGFBP2 is also expressed
in a wide range of other tissue types, including both epithelial
and mesenchymal cells [see Ref. (88), proteinatlas.org (89), and
encode (90)], therefore the local levels of IGFBP2 are likely to play
an important part in how the tissue responds to circulating IGFs.
Approaches to detect changes in protein or RNA levels of IGFBP2
within tumors have been used to hint at whether IGFBP2 might
act in a tumor suppressive or oncogenic manner, however, within
a given tumor type the expression of IGFBP2 can vary greatly,
so below we examine the mechanisms, which regulate IGFBP2
expression in tumors.
PROMOTER METHYLATION
Promoters, including the IGFBP2, can become hyper- or hypo-
methylated relative to the normal state during tumorigenesis. The
IGFBP2 promoter has been shown to be hypermethylated, in a
subset of tumors, including 8% of small cell lung carcinomas
(86), >20% of renal cell carcinomas (91), ~30% squamous cell
lung cancers (86), 40% of colorectal cancers (92), >70% lung
adenocarcinomas (86), and 75% hepatomas (93). The hyperme-
thylation results in reduced IGFBP2 expression, as demonstrated
by Yazawa et al. with good correlation between IGFBP2 promoter
methylation and IGFBP2 protein expression detected by IHC (86).
The low expression of IGFBP2 observed in some glioblastoma cell
lines, is associated with methylation of the IGFBP2 promoter and
can be restored with 5-azacytadine treatment suggesting regula-
tion by DNA methyltransferase 1 (DNMT1) (94). Also, DNMT3L
knockdown in embryonic stem cells results in elevated IGFBP2
expression (95), suggesting promoter methylation is an important
regulator of IGFBP2 expression. The observation that IGFBP2 is
hypermethylated in lung and liver cancers is somewhat surprising
as elevated plasma levels have been described for these diseases
(57, 87); however, the higher plasma levels of IGFBP2 may rep-
resent a systemic response to cancer, or the confounding factors
described above. Further assessment of the inactivation of the
IGFBP2 locus will be greatly aided by The Cancer Genome Atlas
project (http://cancergenome.nih.gov/).
NORMAL VERSUS ABERRANT REGULATION
Insulin-like growth factor binding protein 2 expression is greatly
influenced by hormonal factors and both positive and negative
regulators of IGFBP2 expression have been described, as reviewed
in Ref. (88). Interestingly, the same hormone can have differ-
ing effects depending upon the tissue. As an example, estradiol
(E2) acts on the hippocampus to increase IGFBP2 expression (96)
whereas in the cortex IGFBP2 expression is reduced (97). Estradiol
also reflects an interesting example of how we interpret the role
of IGFBP2 in cancer, as previously described, IGFBP2 is gener-
ally considered to be oncogenic in breast cancer; however, IGFBP2
expression, in vivo, is induced by estradiol in normal breast tissue
(98), whereas in the rat mammary adenocarcinoma, R3230AC,
IGFBP2 expression is reduced following E2 treatment (99). In the
breast cancer cell line, MCF7 IGFBP2 expression is also elevated
by E2 (100), suggesting that this cell line is responding in the same
way as normal tissue. Estrogen receptor (ER) status directly cor-
relates with IGFBP2 expression in breast cancer, with ER-positive
cancers having higher levels of IGFBP2 than ER-negative cancers
(80, 101, 102), and therefore the high levels of IGFBP2 may sim-
ply reflect a functional ER pathway. In order to better understand
whether regulation of IGFBP2 expression is de-regulated in can-
cer, it will be important to further establish how it is regulated in
the physiological setting.
REGULATION BY PROTEASES
In addition to the aforementioned disconnect between plasma
levels and tumor levels of IGFBP2, there are also reports demon-
strating that IGFBP2 mRNA and protein levels do not always
correlate (103). Protease cleavage of IGFBP2 could be partially
responsible for the lack of association, and also help to explain
the differential findings of IGFBP2’s role in cancer. There are a
number of proteases, which cleave the mature IGFBP2 peptide,
these include calpain (104), pappalysin A (105), kallikrein-2 (106),
and MMP7 (107). Plasmin and MMP1 also cleave IGFBP2; how-
ever, the cleavage sites have not been defined (108). In addition,
IGFBP2 is also cleaved at additional sites; however, the responsible
proteases have not been identified (109). IGFBP2 cleavage reduces
its affinity for IGFI and IGF2 (110–112), allowing IGFs to mediate
their functions through the IGF1R. Thus, it is important to reflect
on the nature of IGFBP2 in carcinogenesis as calpain (113), MMP1
(114), MMP7 (114), and kallikrein-related peptidases (115) have
also been described to be elevated or activated in various cancer
types and may lead to inactivation of the protein. Many reagents
used to detect the IGFBP2 protein are not able to distinguish
whether IGFBP2 is in its full-length form. Fragments of IGFBP2
can be detected by the antibodies often used for immunohisto-
chemical detection of IGFBP2 (110). To our knowledge, only one
report has assessed IGFBP2 expression with multiple antibodies,
targeting the C and N termini of IGFBP2. This work demon-
strated a correlation between a cleaved N-terminal fragment of
IGFBP2 and the protease ADAMTS1 in glioblastoma (116) sug-
gesting IGFBP2 is not in a full-length form and therefore may be
unable to bind IGFs.
Insulin-like growth factor binding protein 2 cleavage may result
in enhanced proliferation mediated by IGFs but it has also been
proposed that the cleaved fragments of IGFBP2 have additional
roles. C-terminal fragments of IGFBP2 are able to promote pro-
liferation of rat chondrocytes (117), and a recent report, which
demonstrates that nuclear IGFBP2 can drive VEGF expression
demonstrated that a nuclear localization sequence (NLS) is present
in the linker region of IGFBP2 (118); interestingly, this region is the
site of many cleavage events and may lead to exposure of the NLS.
The importance of establishing whether IGFBP2 is cleaved in
cancer tissue has recently been demonstrated by Soh et al. (108),
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where a protease-resistant IGFBP2 was more effective at inhibiting
IGF1-induced proliferation of the MCF7 cell line than wild-type
IGFBP2. Interestingly, protease resistant IGFBP2 was also able to
suppress tumor growth in vivo. Furthermore, the MCF7 cell line
is known to secrete low levels of full-length IGFBP2 compared to
other cancer cell lines even though the mRNA and intracellular
protein levels of IGFBP2 are comparable (119), suggesting high
levels of proteolytic degradation.
Reflecting on the cleaved status of IGFBP2 in cancer may also
help to explain some of the contradictory evidence regarding its
tumor suppressive/oncogenic role in carcinogenesis. For example,
the elevated expression of the IGFBP2 protein observed in vari-
ous cancers may represent a response to suppress tumor growth,
mediated by IGFs; however, pro-tumorigenic proteases may ulti-
mately inactivate this response. Enhanced proteolysis of IGFBP2
has been described in proliferating cells, and can be inhibited
by targeting proteases (120). Therefore, the observation that a
protease-resistant IGFBP2 can suppress tumor growth (108) cre-
ates the exciting opportunity to target proteases and potentially
restore the suppressive actions of IGFBP2.
INTRA-TUMOR VARIABILITY
In addition to the variation of IGFBP2 expression between differ-
ent tumors, there is also further variation of IGFBP2 expression
levels, within an individual tumor. While high grade glioblas-
toma, which are frequently observed to have elevated IGFBP2 level,
also have regions of reduced IGFBP2 expression, which have been
shown to be at the invasive front of the tumor (121). Therefore,
this data would suggest that IGFBP2 loss correlates with enhanced
invasive potential, as observed in other models (59). Interestingly,
this is also supported by an in vivo model of malignant brain
tumor growth and invasion, where rapidly growing non-invasive
tumors have high levels of IGFBP2 compared to invasive tumors,
which had low/undetectable IGFBP2 levels (122). Furthermore,
the oxygenation of a tumor varies depending on blood supply to
different regions of the tumor, hypoxia has been shown to regulate
IGFBP2 expression (88, 123–126) and should also be considered
when scoring IGFBP2 expression in tumor samples.
REGULATION OF IGFBP2 EXPRESSION BY TUMOR SUPPRESSORS AND
ONCOGENES
There are a number of additional factors,which are known to influ-
ence IGFBP2 expression, and therefore how we evaluate its role in
cancer. There are now a number of reports, which demonstrate a
connection between PTEN levels and those of IGFBP2 (127–130).
PTEN mutation in glioma is associated with high levels of IGFBP2
(130) suggesting that IGFBP2 could be a marker of PTEN muta-
tion. Similarly, mutation of KRAS also induces IGFBP2 expression
(131). IGFBP2 expression has also been shown to correlate with
TP53 mutational status. While it has been demonstrated that wild-
type p53 is required for IGFBP2 induction following irradiation
(132), the regulation of IGFBP2 by p53 mutations is, at present,
unclear. In breast cancer, p53 mutation is associated with reduced
secretion of IGFBP2 (133), whereas in glioblastoma, mutant p53
is associated with high levels of IGFBP2 (94). In addition, Ras
mutation, loss of p53 and radiation-induced DNA damage drives
a senescence-associated secretory phenotype (SASP), of which,
elevated IGFBP2 secretion is a component (134). This is also
supported by evidence that mRNA expression is also elevated in
senescence (135–137). Together these findings suggest that the
variation in IGFBP2 expression in tumors may reflect the status
of tumor suppressors, oncogenes, and/or use of radiation therapy,
therefore, the tumor suppressive/oncogenic potential of IGFBP2
should now be evaluated in the context of each mutation in order
to demonstrate whether or not IGFBP2 has a functional role.
CORRELATION OF IGFBP2 EXPRESSION WITH CANCER
PROGRESSION
It has been established that enhanced expression of IGFBP2 is
associated with the progression of tumorigenesis in prostate (27),
breast cancer (138), and glioma (7); however, when the expression
of IGFBP2 is examined further it appears that there are certain
cancer types or subpopulations of cancers, which develop with
little or no expression of IGFBP2. This latter finding goes against
the hypothesis of IGFBP2 being a driver of tumorigenesis, and
suggests that loss of IGFBP2 may also be an important event in
tumors. A detailed examination of ovarian cancers observed that
IGFBP2 expression did not correlate with stage of disease (139),
with similar proportions of tumors having low or high expres-
sion of IGFBP2 at all stages. Interestingly, in the same study, the
authors demonstrate that the expression of IGFBP2 is related to
the type of ovarian cancer, for example, 80% of serous carcinoma
had elevated IGFBP2 whereas 80% of clear cell carcinoma had low
IGFBP2 levels. Similarly, in lung cancer, IGFBP2 is found to be
overexpressed in the majority of small cell lung carcinomas but
reduced in the majority of lung adenocarcinomas (86). Thus, it is
important to consider whether these results demonstrate a corre-
lation of IGFBP2 driving tumorigenesis or are, in fact, reflective
of tumor stage/subtype. These findings suggest that cancers can
develop both in the presence and absence of IGFBP2 and as cancer
sub-types become further defined it will be important to eval-
uate how IGFBP2 expression is regulated among these different
groups. Evaluation of IGFBP2’s role in each group will then pro-
vide a better understanding of it oncogenic and tumor suppressive
potential.
THERAPEUTIC RESPONSE AND IGFBP2
Evaluation of IGFBP2 as a biomarker in the treatment of can-
cer has also generated a dichotomy in how IGFBP2 is perceived.
In some cases, IGFBP2 is found to be a marker of response to
therapy but then others have demonstrated that high levels con-
fer resistance. In the case of IGF1R targeted therapies, McCaffery
et al. (47) demonstrated that there was better response to IGF1R
targeted therapy in patients with low IGFBP2 levels, than patients
with high IGFBP2 and similar results were found in a mouse model
where inhibition with the IGF1R inhibitor BMS-536924, had no
effect in reducing growth of cells expressing high levels of IGFBP2
(140). However, down-regulation of IGFBP2 in rhabdomyosar-
coma is associated with resistance to IGF1R therapy (141). In
response to other therapeutic strategies, tumor samples from
patients receiving chemotherapy/radiotherapy have been shown to
have elevated IGFBP2 levels and suggest that IGFBP2 is a potential
marker of response to these treatments (134) and may be due to a
pro-apoptotic function of IGFBP2 (142). However, high levels of
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IGFBP2 are also linked with resistance to other therapeutics (143–
146) and high levels of IGFBP2 following radio/chemotherapy
also correlate with poor survival in elderly patients with glioblas-
toma (147). Therefore, further evaluation of IGFBP2 in response
to therapy is an area, which requires further investigation.
DIFFERENTIAL FUNCTIONS OF IGFBP2
The binding to IGF1 and IGF2 is common to in vitro models,which
demonstrate either oncogenic or tumor suppressive functions
of IGFBP2 (148). In addition to repressing IGF signaling, IGF-
independent functions have also been described. Overexpression
or addition of recombinant IGFBP2 activates integrin complexes
with integrins α5 and β1 mediating the effects of IGFBP2 (142,
149–151). Through these pathways IGFBP2 reduces adhesion and
promotes proliferation and invasion, some of these activities are
also observed in cell lines that lack the IGF1-receptor (142) and
therefore helps to explain the dichotomy of IGFBP2 functions
in vitro and may also explain the association of high levels of
IGFBP2 with high grade tumors, despite its inhibitory effect on
IGF signaling. It is important to note that these observations have
been made following addition of 100–2000 ng/mL recombinant
IGFBP2, while these levels are within the physiological range of
human plasma these are greater than the levels secreted by cell
lines in culture (151).
CONCLUSION
While there is conflicting evidence as to whether IGFBP2 is tumor
suppressive or oncogenic, this mini-review highlights a number
of factors, which influence our interpretation of these findings.
Through detailing factors, which influence IGFBP2 expression
alongside measurements in patient samples our current under-
standing of its role in cancer could be improved. So far, it is
clear that IGFBP2 has profound effects on cancer cell biology
both in vitro and in vivo and therefore warrants further evalu-
ation of IGFBP2 either as a biomarker or even as a therapeutic.
The tumor suppressive functions of IGFBP2 align with its ability
to bind IGFs while its oncogenic properties of IGFBP2 appear to
be IGF-independent. In the future assessment of IGFBP2’s role in
cancer, it will be important to consider (i) should IGFBP2 levels
be assessed in plasma or the tumor/tumor microenviroment? and
(ii) can we assess the activity status of IGFBP2 alongside expres-
sion levels? either through measuring IGFBP2 cleavage or through
development of a functional assay. Further avenues will also likely
assess whether IGFBP2 is a predictive biomarker for therapeutic
response.
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